Key facts
- This page summarizes Steven H. Stein's Form 4 filing for Theseus Pharmaceuticals, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 14 Feb 2024, 16:03.
Steven H. Stein - 14 Feb 2024 Form 4 Insider Report for Theseus Pharmaceuticals, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 14 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Feb 2024, 16:03:29 UTC
- Prior SEC filing
- 22 Jan 2024
- Next SEC filing
- 20 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bradford Dahms, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Steven H. Stein filed Form 4 for Theseus Pharmaceuticals, Inc. on 14 Feb 2024.
Change
- Previous filing in this sequence was filed on 22 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
THRX
transaction
Derivative
Restricted Stock Units
Disposed to Issuer
- Transaction value
- Shares
- -3,250
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 14 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,250
- Exercise price
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Steven H. Stein is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger.
Footnote F2
Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share.
Footnote F3
Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) $4.05 per Share in cash, without interest and subject to any withholding of taxes; and (ii) one non-transferable contractual contingent value right per Share subject to such Issuer RSU, which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal.